Time and Motion Study to Quantify Time for Tysabri (Natalizumab) Intravenous Versus Subcutaneous to Treat Relapsing-Remitting Multiple Sclerosis in France, Spain, and the United Kingdom
Natalizumab SC offers substantial savings in active HCP time and patient chair time compared with natalizumab IV. HCPs reported higher satisfaction and a preference for natalizumab SC. The HCP time and infusion chair capacity made available with natalizumab SC could be reallocated to other patient-care activities or used to treat additional patients, thereby improving overall healthcare efficiency.
Authors
- E De Cock (ORCID: https://orcid.org/0000-0002-1623-9169)
- Rona Lyn Esquejo-Leon
- Khalil Jomaa
- Carlos Ríos (ORCID: https://orcid.org/0000-0003-0221-8276)
- Peter Oliver-Smith
- Jyothi Menon
Institutions
- Biogen (United States) (US)
- Syneos Health (India) (IN)
- Biogen (Switzerland) (CH)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1007/s40120-026-00888-1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen